May 30, 2019 / 03:00AM GMT
Operator
Ladies and gentlemen, good day, and welcome to the Q4 FY '19 Earnings Conference Call of Glenmark Pharmaceuticals Limited. (Operator Instructions) Please note that this conference is being recorded.
I would now like to hand the conference over to Mr. Jason D'souza. Thank you, and over to you, sir.
Jason D'souza - Glenmark Pharmaceuticals Limited - Senior VP & Head of Corporate Strategy
Thank you, moderator. Welcome to Glenmark's Q4 Earnings Call. We'll start with the review of operations for the quarter ended March 31, 2019. For the quarter ended March 31, 2019, Glenmark's consolidated revenue was at INR 25,634 million recording an increase of 12.44%. For the financial year ended March 31, 2019, Glenmark's consolidated revenue was at INR 98,65 million (sic) [INR 98,654.68 million] as against INR 91,030 million recording an increase of 8.38%.
We would like to give you an update on the 3 businesses, which is Glenmark Pharmaceuticals, Glenmark Life Sciences Ltd. and the newco, which is the innovation business.
Full Year 2019 Glenmark Pharmaceuticals Ltd Earnings Call Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
![](https://static.gurufocus.com/material/money-back-guarantee.png)
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent ![](https://static.gurufocus.com/trust_rating.png)
![](https://static.gurufocus.com/trust_rating.png)
4.6 out of 5
Trustpilot
![](https://static.gurufocus.com/trust.png)